Physician profile
William Dudding
NPI 1679592604
$3,659.87
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $454 · 2021: $1,222 · 2022: $417.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $525.83 | 2019-2022 | |
| Glaxosmithkline, LLC. | $477.75 | 2019-2022 | |
| Novo Nordisk INC | $378.08 | 2019-2022 | |
| Abbvie INC. | $333.83 | 2019-2022 | |
| Allergan, INC. | $245.97 | 2019-2020 | |
| Pfizer INC. | $211.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $195.91 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.07 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $158.51 | 2021-2022 | |
| Amarin Pharma, INC. | $156.70 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $121.97 | 2020 | |
| Novartis Pharmaceuticals Corporation | $98.92 | 2019-2022 | |
| Astellas Pharma US INC | $87.56 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.87 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $65.92 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.62 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $29.91 | 2022 | |
| Dexcom, INC. | $29.81 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $27.57 | 2020 | |
| Abbott Laboratories | $19.72 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.12 | 2019 | |
| Vanda Pharmaceuticals INC. | $18.72 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.76 | 2022 | |
| Dermira, INC. | $14.94 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.32 | 2020 | |
| Eisai INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dudding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.